Premium
Combination chemotherapy in the management of breast cancer metastases
Author(s) -
Deemarsky L. Y.,
Chernomordikova M. F.
Publication year - 1970
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197010)26:4<771::aid-cncr2820260405>3.0.co;2-y
Subject(s) - medicine , cyclophosphamide , chemotherapy , breast cancer , surgery , cancer , oncology
The method of combined chemotherapy is based on the assumption that the simultaneous injection of combinations of divergent action (antimetabolites that detain the inclusion of some nucleonic acids in the RNA of tumor cell and alkylating agents that react with the phosphate groups of DNA of tumor cell) leads to the synergistic action of these agents. The treatment of 31 patients with mostly hematogenous metastases gave objective remission and stabilization of the process in 22 cases in 13 cases of this series (2 lung metastases, 8 bone metastases, and 3 cerebral metastases), the complete reduction of metastatic foci was attained. The general doses were 4.5g–5.5g of 5‐FU and 4.0 g–6.0 g of cyclophosphamide. No serious complications were noted. The repeated courses of chemotherapy must be performed every 6‐8 weeks, even in cases of remission.